David A. Siegel Editas Medicine, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,129,000 shares of EDIT stock, worth $2.72 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,129,000

Previous 856,500 31.82%

Holding current value

$2.72 Million

Previous $4 Million 3.75%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.39 - $5.96 $923,775 - $1.62 Million	272,500 Added 31.82%	1,129,000 $3.85 Million
Q2 2024 Aug 14, 2024	SELL	$4.67 - $7.28 $1.76 Million - $2.75 Million	-377,800 Reduced 30.61%	856,500 $4 Million
Q1 2024 May 15, 2024	BUY	$7.03 - $11.07 $652,384 - $1.03 Million	92,800 Added 8.13%	1,234,300 $9.16 Million
Q4 2023 Feb 14, 2024	BUY	$6.25 - $11.11 $415,625 - $738,815	66,500 Added 6.19%	1,141,500 $11.6 Million
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $1.97 Million - $2.65 Million	284,600 Added 36.01%	1,075,000 $8.39 Million
Q2 2023 Aug 14, 2023	SELL	$6.36 - $11.47 $703,416 - $1.27 Million	-110,600 Reduced 12.28%	790,400 $6.5 Million
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $1.37 Million - $2.24 Million	-194,500 Reduced 17.75%	901,000 $6.53 Million
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $158,080 - $250,990	19,000 Added 1.76%	1,095,500 $9.72 Million
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $1.22 Million - $1.94 Million	100,000 Added 10.24%	1,076,500 $13.2 Million
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $929,070 - $1.99 Million	93,000 Added 10.53%	976,500 $11.6 Million
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $1.75 Million - $3.43 Million	124,100 Added 16.34%	883,500 $16.8 Million
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $9.2 Million - $14.1 Million	346,500 Added 83.92%	759,400 $20.2 Million
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $9.97 Million - $18.5 Million	-253,900 Reduced 38.08%	412,900 $17 Million
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $2.23 Million - $4.04 Million	71,300 Added 11.97%	666,800 $37.8 Million
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $7.42 Million - $16.9 Million	186,900 Added 45.74%	595,500 $25 Million
Q4 2020 Feb 16, 2021	SELL	$27.07 - $84.35 $6.08 Million - $18.9 Million	-224,600 Reduced 35.47%	408,600 $28.6 Million
Q3 2020 Nov 16, 2020	BUY	$28.06 - $37.16 $757,620 - $1 Million	27,000 Added 4.45%	633,200 $17.8 Million
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $16,650 - $30,906	-900 Reduced 0.15%	606,200 $17.9 Million
Q1 2020 May 15, 2020	BUY	$14.88 - $32.78 $2.82 Million - $6.22 Million	189,600 Added 45.41%	607,100 $12 Million
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $2.23 Million - $3.74 Million	114,500 Added 37.79%	417,500 $12.4 Million
Q3 2019 Nov 14, 2019	BUY	$22.49 - $26.81 $2.91 Million - $3.46 Million	129,200 Added 74.34%	303,000 $6.89 Million
Q2 2019 Aug 14, 2019	BUY	$20.48 - $27.76 $1.27 Million - $1.72 Million	61,900 Added 55.32%	173,800 $4.3 Million
Q1 2019 May 15, 2019	BUY	$19.43 - $26.41 $108,808 - $147,896	5,600 Added 5.27%	111,900 $2.74 Million
Q4 2018 Feb 14, 2019	BUY	$18.19 - $31.79 $347,429 - $607,189	19,100 Added 21.9%	106,300 $2.42 Million
Q3 2018 Nov 14, 2018	BUY	$27.65 - $38.39 $44,240 - $61,424	1,600 Added 1.87%	87,200 $2.78 Million
Q2 2018 Aug 14, 2018	BUY	$31.4 - $41.01 $1.1 Million - $1.44 Million	35,100 Added 69.5%	85,600 $3.07 Million
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $716,160 - $1.06 Million	24,000 Added 90.57%	50,500 $1.67 Million
Q4 2017 Feb 14, 2018	BUY	$21.89 - $31.34 $580,085 - $830,510	26,500	26,500 $814,000

Others Institutions Holding EDIT

# of Institutions

247

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $166M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account